Technetium (99mTc) tilmanocept
From Wikipedia, the free encyclopedia
 | |
|---|---|
| Systematic (IUPAC) name | |
| Dextran 3-[(2-aminoethyl)thio]propyl 17-carboxy-10,13,16-tris(carboxymethyl)-8-oxo-4-thia-7,10,13,16-tetraazaheptadec-1-yl 3-[[2-[[1-imino-2-(D-mannopyranosylthio)ethyl]amino]ethyl]thio]propyl ether technetium-99m complexes | |
| Clinical data | |
| Trade names | Lymphoseek |
| AHFS/Drugs.com | entry |
| Pregnancy cat. | C (US) |
| Legal status | ℞-only (US) |
| Routes | Intradermal, subcutaneous |
| Pharmacokinetic data | |
| Half-life | 1.75 to 3.05 hours at injection site |
| Identifiers | |
| ATC code | V09IA09 |
| Chemical data | |
| Formula | (C6H10O5)n(C19H28N4O9S99mTc)3–8(C13H24N2O5S2)12–20(C5H11NS)0–17 |
| Mol. mass | 15,281–23,454 g/mol[1] |
Technetium (99mTc) tilmanocept, trade name Lymphoseek, is a radiopharmaceutical diagnostic imaging agent approved by the U.S. Food and Drug Administration (FDA) for the imaging of lymph nodes.[1][2] It is used to locate those lymph nodes which may be draining from tumors, and assist doctors in locating those lymph nodes for removal during surgery.[3]
References
- ↑ 1.0 1.1 FDA Professional Drug Information
- ↑ http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm343525.htm
- ↑ Marcinow, A. M.; Hall, N.; Byrum, E.; Teknos, T. N.; Old, M. O.; Agrawal, A. (2013). "Use of a novel receptor-targeted (CD206) radiotracer, 99mTc-tilmanocept, and SPECT/CT for sentinel lymph node detection in oral cavity squamous cell carcinoma: Initial institutional report in an ongoing phase 3 study". JAMA otolaryngology-- head & neck surgery 139 (9): 895–902. doi:10.1001/jamaoto.2013.4239. PMID 24051744.
| ||||||||||||||||||||||||||||||||
This article is issued from Wikipedia. The text is available under the Creative Commons Attribution/Share Alike; additional terms may apply for the media files.